MSC therapy for inflammatory bowel disease

Inflammatory bowel disease (IBD) belongs to the group of diseases characterized by idiopathic inflammation of the digestive tract organs. Two basic IBD types are distinguished: ulcerative colitis and Crohns disease. The IBD symptoms including vomiting and diarrhea, abdominal pain, rectal bleeding, a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mikhail A. Konoplyannikov, Oleg V. Knyazev, Vladimir P. Baklaushev
Formato:	article
Lenguaje:	RU
Publicado:	Eco-vector 2021
Materias:	clinical trials inflammatory bowel disease ulcerative colitis crohn’s disease cell therapy mesenchymal stromal cells regenerative medicine Medicine R
Acceso en línea:	https://doaj.org/article/16d287a9f09644518734e234e1e231bd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:16d287a9f09644518734e234e1e231bd
record_format	dspace
spelling	oai:doaj.org-article:16d287a9f09644518734e234e1e231bd2021-11-30T18:15:21ZMSC therapy for inflammatory bowel disease2220-30952618-862710.17816/clinpract64530https://doaj.org/article/16d287a9f09644518734e234e1e231bd2021-03-01T00:00:00Zhttps://journals.eco-vector.com/clinpractice/article/viewFile/64530/pdfhttps://doaj.org/toc/2220-3095https://doaj.org/toc/2618-8627Inflammatory bowel disease (IBD) belongs to the group of diseases characterized by idiopathic inflammation of the digestive tract organs. Two basic IBD types are distinguished: ulcerative colitis and Crohns disease. The IBD symptoms including vomiting and diarrhea, abdominal pain, rectal bleeding, anemia have a significant negative impact on the general patients state of health. Besides, IBD patients are susceptible to the risk of a number of serious diseases such as colorectal cancer, thrombosis and primary sclerosing cholangitis. More than 4 million people in the USA and Europe suffer from IBD, with 70000 new cases diagnosed yearly in the USA only. In some cases, a surgical removal of the damaged digestive tract fragments is required to treat severe IBD forms. However, drug therapy of IBD has mainly been used in the last decades. The rate of remission with application of traditional IBD therapy is estimated as 20-30%, and is still no higher than 50% with the combined therapy. Cell therapy has been proven to be a very promising approach in the IBD treatment. In our review, we discuss mesenchymal stromal cells (MSC) and the most important preclinical and clinical results of their application for the IBD therapy.Mikhail A. KonoplyannikovOleg V. KnyazevVladimir P. BaklaushevEco-vectorarticleclinical trialsinflammatory bowel diseaseulcerative colitiscrohn’s diseasecell therapymesenchymal stromal cellsregenerative medicineMedicineRRUКлиническая практика , Vol 12, Iss 1, Pp 53-65 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	clinical trials inflammatory bowel disease ulcerative colitis crohn’s disease cell therapy mesenchymal stromal cells regenerative medicine Medicine R
spellingShingle	clinical trials inflammatory bowel disease ulcerative colitis crohn’s disease cell therapy mesenchymal stromal cells regenerative medicine Medicine R Mikhail A. Konoplyannikov Oleg V. Knyazev Vladimir P. Baklaushev MSC therapy for inflammatory bowel disease
description	Inflammatory bowel disease (IBD) belongs to the group of diseases characterized by idiopathic inflammation of the digestive tract organs. Two basic IBD types are distinguished: ulcerative colitis and Crohns disease. The IBD symptoms including vomiting and diarrhea, abdominal pain, rectal bleeding, anemia have a significant negative impact on the general patients state of health. Besides, IBD patients are susceptible to the risk of a number of serious diseases such as colorectal cancer, thrombosis and primary sclerosing cholangitis. More than 4 million people in the USA and Europe suffer from IBD, with 70000 new cases diagnosed yearly in the USA only. In some cases, a surgical removal of the damaged digestive tract fragments is required to treat severe IBD forms. However, drug therapy of IBD has mainly been used in the last decades. The rate of remission with application of traditional IBD therapy is estimated as 20-30%, and is still no higher than 50% with the combined therapy. Cell therapy has been proven to be a very promising approach in the IBD treatment. In our review, we discuss mesenchymal stromal cells (MSC) and the most important preclinical and clinical results of their application for the IBD therapy.
format	article
author	Mikhail A. Konoplyannikov Oleg V. Knyazev Vladimir P. Baklaushev
author_facet	Mikhail A. Konoplyannikov Oleg V. Knyazev Vladimir P. Baklaushev
author_sort	Mikhail A. Konoplyannikov
title	MSC therapy for inflammatory bowel disease
title_short	MSC therapy for inflammatory bowel disease
title_full	MSC therapy for inflammatory bowel disease
title_fullStr	MSC therapy for inflammatory bowel disease
title_full_unstemmed	MSC therapy for inflammatory bowel disease
title_sort	msc therapy for inflammatory bowel disease
publisher	Eco-vector
publishDate	2021
url	https://doaj.org/article/16d287a9f09644518734e234e1e231bd
work_keys_str_mv	AT mikhailakonoplyannikov msctherapyforinflammatoryboweldisease AT olegvknyazev msctherapyforinflammatoryboweldisease AT vladimirpbaklaushev msctherapyforinflammatoryboweldisease
_version_	1718406365012033536

MSC therapy for inflammatory bowel disease

Ejemplares similares